Infinity Pharmaceuticals Now Covered by Nomura (INFI)
Analysts at Nomura started coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI) in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating on the stock.
Infinity Pharmaceuticals (NASDAQ:INFI) traded up 2.64% on Wednesday, hitting $12.83. The stock had a trading volume of 127,250 shares. Infinity Pharmaceuticals has a 52 week low of $11.57 and a 52 week high of $50.51. The stock has a 50-day moving average of $13.71 and a 200-day moving average of $16.53. The company’s market cap is $616.9 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Thursday, November 7th. The company reported ($0.71) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.75) by $0.04. Analysts expect that Infinity Pharmaceuticals will post $-2.83 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on INFI. Analysts at Credit Suisse downgraded shares of Infinity Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, December 12th. They now have a $20.00 price target on the stock. Analysts at UBS AG downgraded shares of Infinity Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $30.75.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.